Business Daily Media

Times Advertising

.

U.S. Food Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma

  • Written by PR Newswire
U.S. Food Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma

MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T) therapy for the treatment of neuroblastoma. Under...

“Time is running out to get Payday ready,” Brighter Super urges

Superannuation fund Brighter Super is encouraging business owners to prepare now for Payday Super, ahead of the new laws taking effect from 1 July...

PayNuts Unveils Expanded Integrated Solutions and Refreshed Brand to Support Australian SMEs

PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...

The Rise of Mobile-First Venues

Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems  As Australian hospitality venues grapple with...